GENE ONLINE|News &
Opinion
Blog

2021-07-04| Asia-Pacific

Australia’s BiomeBank Seeks Approval for the World’s First Microbial Therapy

by Tyler Chen
Share To

Microbiomes have been proven to be linked to several diseases, and scientists worldwide have started to explore the potential of fecal microbiota transplantation (FMT). 

 

World-First Microbial Therapy

On July 1st, Australia’s BiomeBank submitted its Clostridioides difficile and Ulcerative Colitis treatment to the Therapeutic Goods Administration (TGA) for market authorization. And if the therapy is approved, it would be the first drug for microbial therapy.

“We’re positioning BiomeBank as a global leader in microbial drug development with a GMP facility in South Australia, a first-generation microbial therapy now submitted for approval and a rapidly growing portfolio of second-generation products in the pipeline,” said Thomas Mitchell, CEO of BiomeBank.

The drug has already been used as an alternative to ulcerative colitis treatment. It is designed to treat patients with recurrent C. difficile and mild to moderate ulcerative colitis by FMT.

 

BiomeBank Raises $100,000 to Tackle Challenges in FMT Research

Established in 2016, BiomeBank established the first microbial therapy production site in Australia. In mid-2021, it raised $30 million from VC investors to continue research and drug development. The company also has plans to develop microbiome drug products and expand its reach in the Asia Pacific region.

On June 24th,  BiomeBank announced a collaboration with RMIT University in Australia. In addition, it received $100,000 in funding from the Innovative Manufacturing Cooperative Research Centre (IMCRC) to develop bioreactor technology to increase the scale of FMT and decrease the cost. 

Related Article: AbbVie’s JAK1 Inhibitor Aces Ulcerative Colitis Trial, Prospers Amid Tough Regulatory Climate

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Rebyota Passes Through FDA To Become First Approved Fecal Microbiota Product
2022-12-05
Bristol Myers Squibb’s Ulcerative Colitis Treatment Gains Further Validation
2022-10-25
APAC-Focused Novotech Buys US CRO and Expands Global Footprint
2022-05-06
LATEST
Relmada Blames ‘Implausible Placebo Results’ on Depression Drug’s Failure Again
2022-12-07
Using Sound Waves to Sort Blood-Based Nanoparticles
2022-12-07
Summit Bets $5 Billion On Akeso’s Bispecific Antibody
2022-12-07
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
2022-12-07
Novartis’ Pluvicto Continues Winning Streak In Prostate Cancer Indication
2022-12-07
Algernon Wins FDA Orphan Drug Designation For Rare Lung Disease Candidate
2022-12-07
European Commission Continues Fight with Illumina and Orders Grail Acquisition Divestment
2022-12-07
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
2023-01-09
JPM Annual Healthcare Meeting 2023
San Francisco, USA
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!